How Sanofi S.A. Makes Money

The drug is co-developed and co-commercialized with Regeneron Pharmaceuticals under a 2007 collaboration agreement; Sanofi records global sales and shares profits with Regeneron, while paying royalties on net sales. This global footprint reduces dependence on any single market and provides access to high-growth emerging markets, though China faces pricing pressure from volume-based procurement. Third, Sanofi's vaccine division — while historically a strength and the world's largest dedicated vaccine business — faces pricing pressure and competitive threats. The pediatric vaccine market faces pricing pressure from government procurement. The Philippine FDA permanently revoked Dengvaxia's license in February 2019, and criminal investigations into Sanofi executives continue. Seventh, Sanofi faces regulatory and pricing pressure globally. In the US, the Inflation Reduction Act's Medicare drug price negotiation program could eventually affect Dupixent's pricing power. In China, volume-based procurement and national reimbursement drug list changes create pricing volatility, as evidenced by the 10.4% Q4 2024 sales decline attributed to inventory effects ahead of reimbursement changes. In Europe, reference pricing and health technology assessment requirements continue to constrain pricing flexibility. However, the 2030 peak sales target assumes continued pricing power and no significant biosimilar competition, both of which carry uncertainty.

That is Sanofi in 2024, a pharmaceutical giant whose fate has become inextricably linked to a monoclonal antibody born from a 2007 partnership with Regeneron Pharmaceuticals. This partnership structure means Sanofi retains approximately 55-60% of Dupixent's economics after Regeneron's share, though exact terms vary by territory. This segment faces structural decline as patents expire and biosimilars enter, with management actively streamlining the portfolio to focus on assets with remaining growth potential. The company's operating model emphasizes pipeline-driven growth, with management targeting high single-digit revenue growth in 2025 and low double-digit business EPS growth, supported by continued Dupixent expansion, new product launches, and operational efficiency initiatives expected to save $2.2 billion by end of 2025. Yet this same concentration creates vulnerability: if Dupixent's growth stalls or biosimilars arrive earlier than expected, Sanofi's revenue base would face a gap that the current pipeline cannot immediately fill. Management's guidance for high single-digit 2025 sales growth and low double-digit business EPS growth assumes successful execution of multiple parallel initiatives: COPD launch acceleration, tolebrutinib approval in MS, amitelimab Phase 3 success, and integration of acquired assets. Sanofi's AA credit rating and 30-year dividend growth streak provide financial stability, but the strategic challenge is unprecedented in the company's modern history. However, Sanofi's R&D productivity has historically lagged peers, with a lower rate of new molecular entity approvals per dollar invested compared to companies like Novartis and Roche. The 'Play to Win' strategy addresses this by prioritizing leading or first-in-class assets and reallocating resources from lower-priority areas like general oncology to immunology and rare diseases. Research and development expenses increased 14.6% to $8.1 billion ($8.0 billion), representing 18.0% of revenue, as Sanofi accelerated investment in pipeline assets including tolebrutinib, amitelimab, and the expanding Dupixent indication program. Full-year 2025 guidance anticipates high single-digit sales growth at CER and low double-digit business EPS growth before share buyback impact. In oncology, Sanofi is a relatively small player compared to Merck, Bristol Myers Squibb, and AstraZeneca, requiring significant investment to build competitive positioning. While the consumer healthcare unit is non-core to the biopharma strategy, the separation requires careful management of transition services, employee retention, and financial restructuring. Any delay or valuation disappointment would undermine investor confidence. This capability, if sustained, could accelerate pipeline development and reduce the time and cost required to replace Dupixent's eventual revenue contribution. Sanofi's growth strategy under CEO Paul Hudson's 'Play to Win' framework, first introduced in 2019 and updated in 2023, centers on four pillars: focus on key growth drivers, operational excellence, R&D prioritization, and strategic business development. The first pillar concentrates resources on Dupixent, rare diseases, vaccines, and new product launches while actively managing decline in General Medicines. In 2024, launches contributed 11% of total sales, up from 8% in 2023, with Beyfortus, ALTUVIIIO, and Nexviazyme as primary contributors. The 2025 guidance targets continued launch contribution growth as these products mature and new assets including tolebrutinib and amitelimab enter the market. These savings are being reinvested into R&D and commercial support for growth assets. In 2024, Sanofi reallocated resources from general oncology to immunology and rare diseases, reflecting a sharper strategic focus. The company is also investing in digital capabilities, including AI-driven drug discovery through the plai platform, digital twins for clinical development, and predictive analytics for supply chain optimization. Geographic expansion remains a priority, particularly in China where Sanofi faces near-term pricing pressure but maintains long-term growth potential, and in emerging markets where vaccine demand and access to specialty medicines continue to expand. Sanofi's strategic horizon is defined by three concurrent imperatives: maximizing Dupixent's remaining growth runway, building a pipeline capable of replacing its revenue contribution before patent expiration, and completing the transformation to a pure-play biopharmaceutical company. The pipeline replacement strategy centers on several high-potential assets. The vaccine pipeline includes next-generation influenza vaccines, mRNA platforms developed through the partnership with Translate Bio (acquired 2021), and combination vaccines. The strategic separation of Opella, expected to close in Q2 2025, will transform Sanofi's financial profile by removing a lower-margin, slower-growing business and enabling sharper focus on biopharma operations. The AI-driven drug discovery platform, plai, aims to reduce R&D costs and accelerate target identification, with reported success in identifying novel targets and optimizing clinical trial design. Jean-François Dehecq and René Sautier, two Elf executives, established Sanofi with a clear mandate: acquire fragmented pharmaceutical laboratories across France and build a consolidated European pharmaceutical group. The early business model was straightforward — a 'buy and build' investment vehicle financed entirely by Elf's capital reserves, without external seed funding. Within two years, Sanofi had integrated over ten small laboratories, overcoming skepticism from the medical establishment and establishing a culture of growth through acquisition. In 1980, Sanofi acquired the Clin-Midy group, significantly expanding its R&D capabilities and therapeutic breadth. The 1994 acquisition of Sterling Winthrop's prescription drug business provided critical US market access, establishing the transatlantic footprint that would prove essential for future growth. Elf Aquitaine and L'Oréal retained significant stakes, providing financial stability while the new entity focused on pharmaceutical R&D and marketing. Bioverativ added hemophilia therapies Eloctate and Alprolix, while Ablynx brought Nanobody technology and caplacizumab for acquired thrombotic thrombocytopenic purpura.